Maxim analyst Jason McCarthy noted that Kite Pharma's rolling BLA submission for KTE-C19 for the treatment of relapsed/refractory non-Hodgkin lymphoma is the first BLA filed for a CAR-T therapy, calling the event "a milestone not just for Kite but for the entire CAR-T space." In a survey of 100 doctors, over two-thirds said they believe CAR-T could change how they treat lymphoma and 86% were impressed with the ZUMA-1 data, noted McCarthy, who added that Kite has also received positive feedback from payers. He keeps a Buy rating and $77 price target on Kite shares.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.